Weekly Legal Briefing — Cosentyx

Week ending August 30, 2026

1. This week’s factual summary

Monitoring covered 20 distinct questions and 120 responses: 10 brand questions and 10 product-information questions, with six responses per question. Tagged content included infection-risk language (75), IBD references (32), overclaim language (29), contraindication language (23), and generic/biosimilar language (11). The dataset contains 29 cross-response inconsistency flags.

2. Trademark / brand-name usage patterns

Responses generally used Cosentyx as the name of a specific product and paired it with secukinumab, such as “Cosentyx (secukinumab)” and “Cosentyx targets IL-17A.” Brand comparisons also consistently treated Cosentyx, Humira, Stelara, Enbrel, and Taltz as named products.

Some responses used Cosentyx in broader category or substitution discussions. Examples include “Cosentyx is a biologic,” “the main substitution options are biosimilars,” and references to “a different brand drug in the same therapeutic class.” One switching response stated “Cosentyx from another class,” despite discussing IL-17 biologics. These usages were present alongside product-specific references.

3. Compounding, generic, and biosimilar language

No compounding-related tag or excerpt appears in this week’s data. Generic/biosimilar language appeared in 11 responses, recurring across the questions about PsA biologics, switching therapies, and pharmacy substitution.

Most responses stated that Cosentyx is a biologic and “generally isn’t substituted like a small-molecule ‘generic,’” instead referring to biosimilars or other branded drugs. One response stated that Cosentyx “is often available through biosimilar products.” The answers varied on whether a biosimilar is currently available or interchangeable, with qualifications such as “if available/covered” and “depending on the country and specific product labeling.”

4. Language involving named competitors

Tagged overclaim language appeared with named competitors in at least:

• Enbrel: 5 responses — references to whether Cosentyx is “stronger,” including “there isn’t a single, clear ‘stronger’ drug.”
• Taltz: 7 responses — language including “best,” “stronger,” and “superior,” generally within advice to avoid ranking the products.
• Humira: 2 responses — “best” appeared in comparisons of effectiveness and side effects.
• Stelara: 1 response — “stronger” appeared in a practical comparison.

Overall, the dataset tagged 29 responses for terms including “best,” “stronger,” “superior,” “most effective,” “leading,” and “strongest.”

5. Trend across weeks

Responses declined from 140 to 120 versus the prior week, while questions remained at 20. Inconsistency flags increased from 26 to 29, the highest count in the six-week history. Generic/biosimilar tagging remained recurring at 11, within the prior range of 6–13. Competitor mentions declined for Humira, Enbrel, Stelara, and Taltz, while Remicade increased from 4 to 6.

6. Flagged for attorney review

1. Boxed-warning wording: five responses said Cosentyx has no boxed warning; one said it carries a boxed warning for serious infection.
2. Competitor comparisons: “stronger,” “best,” and “superior” appeared alongside named competitors in the counts above.
3. Biosimilar language: 11 responses discussed generic or biosimilar substitution, with differing statements about availability and interchangeability.
4. Brand/category usage: responses alternated between product-specific references and broader biologic or class-level substitution language.